Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo ‐controlled trial in North East Asia

ConclusionBelimumab was efficacious for the treatment of SLE and well tolerated among the South Korean subgroup of patients from the NEA study.

Source: International Journal of Rheumatic Diseases - December 24, 2023 Category: Rheumatology Authors: Chang ‐Hee Suh, Yoonhee Lee, Sang‐Bae Yoo, Holly Quasny, Aldo Amador Navarro Rojas, Anne Hammer, Yeong‐Wook Song, Young Mo Kang, Chul‐Soo Cho, Won Park, Seung‐Ki Kwok, Seung‐Geun Lee, Won Tae Chung, Sang‐Cheol Bae Tags: ORIGINAL ARTICLE Source Type: research